These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000808-40 Randomized, open label, multi-center, phase III study on pharmacokinetics, pharmacodynamics, efficacy and safety of Goserelin 1M Implant HEXAL in patients with advanced prostatic cancer in comparison ... bad-data
Completed, but no date, and reported results 2004-002766-37 Open-label, multi-center, non-controlled follow-up study over 3-months on the safety of Formoterol Easyhaler® in approximately 35 asthmatic pediatric patients initially treated in study 2003-51-DPI-2 bad-data
Reported results 2004-003956-20 Multi-center, double-blind, double-dummy, controlled, randomized phase III study on the tolerability and efficacy of Diclofenac Sodium 150 mg o.d. in comparison to Voltaren® 50 t.i.d. and Voltaren® Di... 2005-09-26 due-trials
Reported results 2005-001279-36 RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO... 2006-09-05 due-trials
Reported results 2005-002873-62 RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF BUSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO... 2006-10-17 due-trials
Ongoing 2006-002506-58 Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age (SGA) not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-000134-39 Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 125 ... 2008-01-08 bad-data
Reported results 2007-000135-26 Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50 (2... 2008-06-05 due-trials
Listed as ongoing, but also has a completion date 2007-001364-72 Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA) 2018-07-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001906-26 Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal in... 2010-02-19 bad-data
Reported results 2007-005235-29 Efficacy and safety of Salmeterol/Fluticasone MDI HEXAL versus SeretideTM EvohalerTM in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, dou... 2009-04-27 due-trials
Reported results 2007-005620-32 Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, doub... 2010-04-02 due-trials
Reported results 2007-005630-36 Double-blind, double-dummy, multi-center, randomized parallel group study to demonstrate therapeutic equivalence of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ 100 Accuhaler™ over a period of 12... 2010-02-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005728-34 Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery... 2010-02-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002696-27 An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w)... 2009-08-04 bad-data
Listed as ongoing, but also has a completion date 2008-004340-37 An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa 2009-08-04 bad-data
Reported results 2008-004351-29 OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER 2009-06-29 due-trials
Completed, reported early 2009-017099-25 A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma. 2010-10-31 not-yet-due
Completed, reported early 2010-018712-32 A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development. 2010-09-30 not-yet-due
Listed as ongoing, but also has a completion date 2010-019522-13 A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, followed by GP2013 or MabThera® maintenance thera... 2018-01-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-021184-32 A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolerant... 2016-11-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024481-22 A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemotherapy 2013-06-17 bad-data
Reported results 2011-001118-32 Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia 2015-09-25 due-trials
Reported results 2011-002871-40 Open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis... 2014-10-31 due-trials
Reported results 2011-004532-58 A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressive ... 2014-02-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-002009-23 A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate t... 2017-06-12 bad-data
Reported results 2012-002011-26 A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to s... 2015-03-30 due-trials
Ongoing, reported early 2012-002039-28 Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® not-yet-due
Reported results 2012-003876-38 A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients wit... 2016-10-12 due-trials
Reported results 2013-000747-11 A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to s... 2016-02-25 due-trials
No trial status on register 2014-001089-90 Study to Test the Product Robustness of a Dry Powder Inhalation Device When Used in Normal Clinical Practice with Young Asthma Patients bad-data
No trial status on register 2015-002802-34 Multicentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature suffering f... bad-data
Listed as ongoing, but also has a completion date and reported results 2015-003433-10 GP17-302 2017-09-26 bad-data